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Abstract 
CXC Chemokine Ligand 12 (CXCL12), also known as Stromal Derived Factor 1 (SDF-
1), is the cognate ligand of CXC Chemokine Receptor Type 4 (CXCR4), a receptor that 
is highly expressed in human breast cancer. The CXCL12/CXCR4 signaling axis has 
been shown to play an important role in breast cancer progression and metastasis. It has 
been shown in previous studies that CXCL12 accelerates tumor growth and metastasis by 
modulating tumor stroma, an active element of the tumor microenvironment, via the 
increased development of carcinoma-associated fibroblasts (CAFs). CAFs, also known as 
myofibroblasts, are often observed in the stromal tissue of invasive breast cancers and 
promote angiogenesis through the recruitment of CXCR4-expressing endothelial 
precursor cells (EPCs). A better understanding of the CXCL12/CXCR4 signaling axis 
could result in the development of novel strategies to prevent breast cancer growth and 
metastasis.  
 
CXCL12 conventional knockout mice have been previously generated. However, these 
mice are neonatally lethal, and are thus insufficient models for the characterization of 
breast cancer growth and metastasis. To circumvent this issue, our lab has begun the 
process of generating CXCL12 conditional knockout mice by inserting a CXCL12 
targeting vector into C57BL/6 mice via blastocyst microinjection, resulting in the 
development of CXCL12 chimeric mice (CXCL12
loxPneo/+
). The CXCL12 targeting vector 
inserted LoxP sequences 1 kb upstream of the start site of the CXCL12 gene, as well as in 
the second intron, flanking exons one and two of the CXCL12 gene. These 
CXCL12
loxPneo/+
 chimeric mice were then crossbreed with C57BL/6 mice and the 
resulting CXCL12
loxPneo/+ 
non-chimeric
 
progeny were characterized using PCR and 
Southern Blot analysis. A successful germline transmission was qualitatively indicated by 
an agouti coat color in the progeny. 
 
In order to confirm the germline transmission of the CXCL12
 
targeting allele, the 
CXCL12
loxPneo/+
 mice were breed with SRY-Box Containing Gene 2 – Cre Recombinase 
(Sox2-Cre) hemizygous mice, resulting in the Cre recombinase-mediated excision of the 
LoxP-flanked CXCL12 gene coding region throughout the early embryo. The neonatal 
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lethality observed in the resulting progeny indicated that the germline transmission of the 
CXCL12 targeting allele worked as intended, since neonatal lethality results from the 
deletion of the CXCL12 gene. 
 
After confirming the germline transmission, the CXCL12
loxPneo/+
 mice were breed with 
Flippase Reporter (FLPeR) mice to remove the Frt-flanked neomycin resistance (Neo) 
gene, which can influence the expression of the floxed CXCL12 gene. The removal of the 
Neo gene from the CXCL12 targeting allele resulted in the generation of CXCL12
loxP/+, 
FLPeR (+/-)
 mice. These CXCL12
loxP/+, FLPeR (+/-) 
mice
 
were then interbreed for several 
generations to generate a sufficiently large population of CXCL12
loxP/loxP, FLPeR (-/-)
 
progeny; the target genotype of this research project.  
 
In future studies, these CXCL12
loxP/loxP, FLPeR (-/-)
 mice will be breed with Fibroblast 
Specific Protein 1 – Cre Recombinase (FSP-Cre) mice in order to delete the LoxP-
flanked CXCL12 gene coding region from stromal fibroblasts in a cell/tissue-type 
specific manner. The deletion of the CXCL12 gene from stromal fibroblasts will result in 
the generation of neonatally viable CXCL12 conditional knockout mice. These CXCL12 
conditional knockout mice will then be used to determine the role of the 
CXCL12/CXCR4 signaling axis in breast cancer growth and metastasis. 
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Introduction 
Breast cancer is the most common form of invasive cancer in women in the United States 
and throughout the world. In the US, approximately 125 new cases of breast cancer are 
diagnosed each year per 100,000 women. Breast cancer is also the second leading cause 
of cancer death among women in the US, where there are approximately 23 deaths per 
100,000 women annually.
3, 4, 6, 16 
 
 A. Incidence 
 
 
 
 
 
 
 
B. Mortality 
 
 
 
 
 
Figure 1. Breast Cancer Incidence and Mortality Statistics in Women Worldwide.
6
 Breast cancer is 
the leading form of invasive cancer among women worldwide in both incidence and mortality rates. Non-
invasive, non-melanomal skin cancers are included in these statistics under the ‘Other and unspecified’ 
categorization. 
 
The prognosis and treatment options for breast cancer patients vary significantly 
depending on the specific classification of their breast cancer. This classification system 
categorizes breast cancers based on four major systems of grading: histopathology, grade, 
stage, and receptor status.  
 
Common histological forms of breast cancer include Ductal Carcinoma in situ (DCIS), 
Lobular Carcinoma in situ (LCIS), Invasive Ductal Carcinoma (IDC), and Invasive 
Lobular Carcinoma (ILC).
2
 Both DCIS and LCIS are non-invasive breast cancers that 
form within the milk ducts and lobules respectively, while IDC and ILC are both invasive 
breast cancers that metastasize into surrounding tissue.
17
 Compared to non-invasive 
breast cancers, invasive breast cancers generally have less favorable prognoses due to 
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their ability to form secondary metastatic tumors. IDC is the most common histological 
form of breast cancer, accounting for approximately 55% of all breast cancers.
18
 
Chemokine receptor CXCR4, the cognate receptor of chemokine ligand CXCL12, has 
been shown to be expressed in 75% of IDC biopsy specimens.
12
 Moreover, the over-
expression of CXCR4 is correlated with a decreased survival rate in IDC patients.
12
 
 
Breast cancer grade is categorized depending on the relative magnitude of differentiation 
of breast cancer cells, and includes three distinct grades. Grade 1 breast cancers are well-
differentiated, grade 2 breast cancers are moderately differentiated, and grade 3 breast 
cancers are poorly differentiated.
2
 Differentiation is defined as the development of cells 
into increasingly specialized forms, and is qualitatively measured by comparing the 
morphology of breast cancer cells with normal breast tissue cells.
 
Breast cancer grade is 
generally determined using the Bloom–Richardson–Elston Grading System, also known 
as the Nottingham Grading System, which provides a comprehensive grade depending on 
three parameters: tubule formation, nuclear pleomorphism, and mitotic count.
19
 Breast 
cancer prognoses become less favorable with a decreasing level of differentiation in 
breast cancer cells.  
        
      A       B          C 
 
 
 
 
 
Figure 2. DCIS Breast Cancer Grades 1-3.
1
 A DCIS Breast Cancer - Grade 1.B. DCIS Breast Cancer - 
Grade 2. C. DCIS Breast Cancer - Grade 3. Breast cancer cells become more irregular and less 
differentiated as the breast cancer grade increases.  
 
Breast cancer stage is determined based on the TNM (Tumor, Nodes, Metastasis) 
Classification of Malignant Tumors, a cancer staging system which classifies a breast 
cancer’s stage from 0 to IV based on three factors: the type of primary breast tumor, the 
size and location of breast cancer cells in various regional lymph nodes, and the 
prevalence of breast cancer metastasis.
20
 The stage of a breast cancer contributes 
significantly to a patient’s prognosis, ranging from a 92% five-year survival rate in stage 
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0 breast cancer patients to a 13% five-year survival rate in stage IV breast cancer 
patients.
21
 
 
Breast Cancer Stage Prognosis (Five-Year Survival Rate) 
0 92% 
I 87% 
II 75% 
III 46% 
IV 13% 
Table 1. Breast Cancer Stage vs. Prognosis.
21
 Breast cancer prognoses become less favorable as the 
breast cancer stage increases. 
 
Breast cancer receptor status classifies the various molecular subtypes of breast cancer 
based on the expression or non-expression of breast cancer associated receptors 
combined with breast cancer tumor grade. Important breast cancer associated receptors 
that influence the receptor status classification include the estrogen receptor (ER), the 
progesterone receptor (PR), and the Human Epidermal Growth Factor Receptor 2 
(HER2/neu).
2
 Different molecular subtypes of breast cancer have varying prognoses and 
recommended treatments. One common molecular subtype of breast cancer is Triple-
Negative Breast Cancer (TNBC), which includes breast cancers that do not express the 
ER, PR, or HER2/neu genes.
22
 It has been shown that poor clinical outcomes in TNBC 
patients are correlated with a high expression of CXCR4.
12
 
 
Chemokines are a family of small cytokines, intercellular signaling proteins that are 
secreted by various types of cells. Chemokines possess the ability to induce chemotaxis, 
the directed movement of somatic cells in response to the presence of a particular 
molecule. Chemokines can either induce cell movement towards an area of higher 
chemokine concentration (positive chemotaxis) or lower chemokine concentration 
(negative chemotaxis).
23
 Due to their ability to induce directed chemotaxis, chemokine 
signaling axes are involved in the progression and metastasis of several cancers, 
including breast cancer. There are 4 major chemokine types: CXC (α), CC (ß), C (γ), and 
CX3C (δ ), each differing in both structure and function.
11
 CXCL12 is a type CXC 
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chemokine (α-chemokine), a type of chemokine that is composed of two N-terminal 
cysteine residues separated by a single amino acid residue.
11
 
 
Chemokine receptors are G Protein-Coupled Receptors (GPCRs), a large family of G 
protein-linked receptors that are involved in signal transduction pathways in eukaryotes. 
The binding of a GPCR to its cognate ligand induces a conformational change in the 
GPCR’s structure, which triggers the phosphorylation of guanosine diphosphate (GDP) to 
guanosine triphosphate (GTP). The phosphorylation of GDP induces the dissociation of 
the G Protein’s α-subunit monomer and ßγ-subunit dimer from the G Protein-linked 
GPCR. The disassociated G protein subunits can then activate other molecules involved 
in the GPCR-associated signal transduction pathway.
12
 
 
Figure 3. Crystal Structure of a GPCR –G Protein Complex.24 Red: GPCR composed of 7 
transmembrane domains. Green: G-Protein α-Subunit. Blue: G-Protein ß-Subunit. Yellow: G-Protein γ-
Subunit. 
 
CXCR4 is a type 4 α-chemokine receptor that binds to CXC chemokine ligands, 
specifically to CXCL12.
8
 Similarly to other GPCRs, the binding of CXCR4 to its cognate 
ligand CXCL12 induces a conformational change in CXCR4’s structure, which triggers 
the phosphorylation of GDP to GTP. The phosphorylation of GDP induces the 
dissociation of the αi-subunit (Gα) and the ßγ-subunit complex (Gßγ) of the CXCR4-
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coupled G protein, which both go on to modulate the downstream signaling of the 
CXCR4/CXCL12 signaling axis.
12 
 
 
Figure 4. CXCL12/CXCR4 Signal Transduction Pathway.
12
 This schematic diagrams the various 
signaling pathways in the CXCR4/CXCL12 signaling axis which result in the induction of chemotaxis 
and/or proliferation in human breast cancer. 
 
These CXCR4-mediated, CXCL12-induced signaling pathways are shown in Figure 4. 
The CXCL12-induced chemotaxis of breast cancer cells is facilitated by intermediary 
genes and proteins, which are activated by the disassociated components of the CXCR4-
coupled G protein (Gα and Gßγ). This CXCL12-induced chemotaxis of breast cancer cells 
can result in breast cancer proliferation and metastasis.
12
  
 
The CXCR4/CXCL12 signaling axis has been shown to mediate organ-selective 
metastasis in breast cancers. Metastatic breast cancer cells were shown to over-express 
CXCR4, while metastasis-susceptible organs (lungs, bones, lymph nodes) were shown to 
over-express CXCL12. These observations indicate that CXCR4 and CXCL12 are 
involved with the trafficking of metastatic breast cancer cells.
12
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Figure 5. CXCL12/CXCR4 Regulation of Organ-Selective Breast Cancer Metastasis.
12
 This model 
diagrams the CXCR4-mediated, CXCL12-induced organ-selective metastasis of breast cancer cells. 
 
As depicted in Figure 5, cancerous mammary epithelial cells initially undergo clonal 
proliferation and invade the local breast tissue. After inducing angiogenesis, the breast 
cancer cells that express CXCR4 detach from the primary tumor and enter the blood 
stream after migrating across the lymphatic and vascular tumor walls. The CXCR4-
expressing breast tumor cells then attach to organs (lungs, bones, lymph nodes) with 
vascular endothelial cells that express high levels of CXCL12 on the surface. The binding 
of CXCR4 to CXCL12 allows the CXCR4-expressing breast tumor cells to migrate into 
the organ tissue, where they can then proliferate, induce angiogenesis and form secondary 
metastatic tumors.
12
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The CXCL12/CXCR4 signaling axis has also been shown to regulate tumor growth and 
metastasis in breast cancers by modulating tumor stroma, an active element of the tumor 
microenvironment.
12
 
 
 
Figure 6. CXCL12-Induced Regulation of Breast Cancer Metastasis.
12
 The CXCL12 released by 
stromal fibroblasts promotes tumorigenesis via two different mechanisms: the stimulation of angiogenesis 
through the recruitment of EPCs (endocrine effect), and the direct stimulation of breast tumor cells through 
CXCR4-expressing breast carcinoma cells (paracrine effect). 
 
The tumor stroma consists of breast tumor cells, fibroblasts, endothelial cells, immune 
cells, and the extracellular matrix (ECM). The CXCL12/CXCR4 signaling axis has been 
shown to accelerate breast cancer growth and metastasis via the increased development of 
carcinoma-associated fibroblasts (CAFs). CAFs are often observed in the stromal tissue 
of invasive breast cancers and promote angiogenesis through the production of ECM as 
well as the secretion of growth factors and chemokines. As shown in Figure 6, CAFs that 
secrete CXCL12 have been shown to stimulate angiogenesis via the recruitment of 
CXCR4-expressing endothelial precursor cells (EPCs) to the tumor stroma.
12
 
12 
 
The CXCR4/CXCL12 signaling axis has been shown to play a role in breast cancer tumor 
proliferation, angiogenesis, and migration, and metastasis. The generation of CXCL12 
conditional knockout mice will allow our lab to determine the role of the 
CXCR4/CXCL12 signaling axis in breast cancer growth and metastasis in in vivo mouse 
model systems. Since mouse model systems can approximate human model systems, the 
determination of the role of CXCR4/CXCL12 signaling axis can eventually lead to the 
development of novel strategies in the treatment of human breast cancer. 
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Methods 
Generation of CXCL12
loxPneo/+ 
Chimeric Mice 
The CXCL12 gene, located on mouse chromosome 6, encodes for 3 isoforms of 
CXCL12: α, ß, and γ. The coding region for CXCL12α contains 3 exons, while the 
coding region for CXCL12ß and CXCL12γ contain 4 exons. In order to knockout all 3 
isoforms of CXCL12, LoxP sequences were inserted 1 kbp upstream of the start site of 
the CXCL12 gene and in the second intron using a CXCL12 targeting vector. Upon the 
introduction of Cre recombinase with FSP-Cre mice, the LoxP-flanked region will be 
deleted from stromal fibroblasts in a cell/tissue-type specific manner via the removal of 
the start site and promoter region of the CXCL12 coding region, resulting in the ablation 
of all isoforms of CXCL12 from stromal fibroblasts.  
 
 
Figure 7. A. CXCL12 Gene Construct. This schematic diagrams the CXCL12 targeting vector, the 
CXCL12 wildtype allele, and the CXCL12 targeting allele. The CXCL12 targeting vector will insert LoxP 
sequences flanking the first two exons of the CXCL12 wildtype allele, as well as a Frt-flanked neomycin 
resistance gene, resulting in the generation of the CXCL12 targeting allele. B. Southern Blot 
Identification of Positive CXCL12 BAC Clones. 1. Wildtype; 2. CXCL12 Targeting Allele (CXCL12 
Positive ES Clone); 3. CXCL12 Wildtype Allele. C. PCR Analysis of LoxP1 Sequence. 1. Wildtype; 2. 
CXCL12 Targeting Allele (CXCL12 Positive ES Clone); 3. CXCL12 Wildtype Allele. 
14 
 
To create a CXCL12 targeting vector, as depicted in Figure 7-A, fragments of the 
CXCL12α gene were amplified from the genomic DNA of a 129/SvEvTac mouse strain 
and confirmed via sequencing. The sequenced CXCL12α gene fragments were then 
cloned using a bacterial artificial chromosome (BAC) DNA construct. Southern blot 
assays were used to identify BAC clones positive for CXCL12. A CXCL12 targeting 
vector was then created by recombineering the CXCL12 DNA from BAC clones into 
PL253 and PL451 vectors. The final vector, consisting of a long 5’ arm (8.1 kbp), a short 
3’ arm (4.0 kbp), and a LoxP-flanked region (7.0 kbp), was linearized with Sal1, a high-
fidelity restriction endonuclease, and transfected into TCl embryonic stem (ES) cells via 
electroporation. Successful transfection was coupled with the development of neomycin 
resistance in the transfected ES cells. The successfully transfected ES cells were selected 
via treatment with neomycin, and transfection was confirmed using southern blot and 
PCR analysis.  
 
         A            B 
 
 
 
 
 
 
Figure 8. Agouti vs. C57BL/6 Mice.
25, 26
 This figure depicts examples of A. Agouti mice and B. C57BL/6 
mice. Agouti mice have a distinctive orange coat color that allows for a clear differentiation between agouti 
and C57BL/6 mice. 
 
Confirmed embryonic stem cell clones were then microinjected into C57BL/6 blastocysts 
to generate male CXCL12
loxPneo/+
 chimeric mice. The male CXCL12
loxPneo/+ 
chimeras 
were breed with female C57BL/6 wildtype mice to generate CXCL12
loxPneo/+ 
non-
chimeric
 
mice. Successful germline transmission was qualitatively indicated by 99.9% 
agouti characteristics in the resulting progeny. 
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Distal Tail Biopsy 
The distal tail biopsy of CXCL12 mice was performed following the guidelines provided 
by the Institutional Animal Care and Use Committee (IACUC), an organization that 
oversees and ensures the humane treatment of animals which are used in scientific 
research. The IACUC guidelines facilitate the maximization of information derived from 
every animal used in scientific research, while simultaneously minimizing procedures 
that could cause discomfort, distress, or pain to laboratory animals.
9
 These guidelines are 
enforced by University Laboratory Animal Resources (ULAR) in almost all in vivo 
biomedical research performed at The Ohio State University.  
 
In order to obtain DNA for the genetic characterization of CXCL12 mice, a distal tail 
biopsy was performed on each CXCL12 mouse. Prior to the excision of the distal tail, 
each mouse’s right ear was tagged using a Stainless Steel Applicator to apply a 4-digit 
numbered tag, in order to facilitate the identification of laboratory mice.  Using a sterile 
pair of surgical scissors, ~5 mm of the distal tail was excised from each mouse prior to 
reaching 21 days of age. Since each distal tail biopsy was performed before each mouse 
reached 21 days of age, prior to the formation of calcified, ossified, and innervated 
vertebrae within the distal 5 mm of the tail, the use of a general anesthetic was not 
required.
9
 After the excision of the distal tail, Kwik-Stop styptic powder with benzocaine, 
an anti-hemorrhagic/hemostatic agent combined with a topical anesthetic, was applied to 
the point of excision in order to promote hemostasis. 
DNA Extraction, Isolation, and Purification 
The DNA extraction of excised CXCL12 mouse distal tail tips was performed using the 
Promega Wizard® Genomic DNA Purification Kit.
10
 A solution consisting of a 25:6 ratio 
of Nuclei Lysis Solution and 0.5 M Ethylenediaminetetraacetic Acid (EDTA) was chilled 
on ice until it turned cloudy/opaque. To each excised tail tip, 600 µL of the pre-chilled 
EDTA/Nuclei Lysis Solution was added to facilitate the lysis of nuclei from mouse tail 
tissue. Afterwards, 17.5 µL of 20 mg/mL Proteinase K, a broad spectrum serine protease, 
was added to each tail sample to induce proteolysis. Each sample was then incubated 
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overnight in a 55º C water bath with gentle shaking until the tail tissue was completely 
dissolved in the lysis solution.  
 
After the overnight incubation, 3 µL of 4 mg/mL RNase A, a ribonuclease that catalyzes 
the degradation of single-stranded RNA (ssRNA), was added to each nuclear lysate.  
Each nuclear lysate sample was incubated at 37ºC for 30 min and then cooled to room 
temperature for 5 min. To each room temperature sample, 200 µL Protein Precipitation 
Solution was added, and the resulting solution was vortexed for 20 s and chilled on ice 
for 5 min. The chilled sample was centrifuged at 14,000 rpm for 4 min, yielding a pellet 
containing the precipitated protein and a supernatant containing the nuclear DNA. To 
prevent the transfer of waste material, the supernatant was immediately transferred to a 
sterile 1.5 mL microcentrifuge tube containing 600 µL room temperature isopropanol. 
The resulting solution was gently mixed via inversion until the white thread-like strands 
of isolated nuclear DNA formed a visible mass. The solution was then centrifuged at 
14,000 rpm for 1 min, yielding a white DNA pellet after decanting the supernatant. To 
each DNA pellet, 600 µL of room-temperature 70% ethanol was added, and the resulting 
solution was gently mixed via inversion to remove hydrophobic contaminants. The mixed 
solution was then centrifuged at 14,000 rpm for 1 min, yielding a white DNA pellet. The 
supernatant was aspirated using a micropipet, and the purified DNA pellet was allowed to 
air-dry for 20 min to remove any remaining traces of 70% ethanol. To each air-dried 
DNA sample, 200 µL of DNA Rehydration Solution was added, and the resulting 
solution was incubated at 4º C overnight to facilitate the solubilization of the purified 
DNA. 
 
Polymerase Chain Reaction (PCR) 
PCR was used to genetically characterize CXCL12 mice via the use of gene-specific 
primers. The Sigma AccuTaq™ LA DNA Polymerase Kit was used to amplify the DNA 
isolated from the excised distal tail tips of CXCL12 mice.
13
 Each CXCL12 mouse was 
genetically characterized by amplifying various combinations of the following gene 
fragments.  
17 
 
LoxP1 
To a 1.5 mL microcentrifuge tube, 1.25 µL AccuTaq LA 10x Buffer, 0.625 µL 10 mM 
dNTP mix, 0.25 µL Dimethyl Sulfoxide (DMSO),  0.25 µL 10 pmol/µL LoxP1-F Primer, 
0.25 µL 10 pmol/µL LoxP1-R Primer, 0.125 µL 5 units/µL AccuTaq LA DNA 
Polymerase, and 9.25 µL Nuclease-Free H2O was added per sample, yielding a Master 
Mix Solution. All primers were dissolved in TE Buffer. After the Master Mix Solution 
was homogenized via centrifugation at 5,000 rpm for 1 min, 12.25 µL was transferred to 
pre-labeled 200 µL PCR tubes. To each PCR tube, 0.25 µL of the previously isolated 
genomic DNA template was added, corresponding to the CXCL12 mouse it was isolated 
from. A Positive Control was created via the addition of 0.25 µL of a LoxP1-homozygous 
DNA template in order to mark the expected size of the PCR product. Additionally, a 
Negative Control was created via the addition of 0.25 µL Nuclease-Free H2O in order to 
determine the presence of DNA template contaminants in any of the components used in 
the master mix solution. Each PCR sample was centrifuged at 5,000 rpm for 1 min prior 
to being amplified in a Thermal Cycler using the following cycling parameters:  
Step Temperature Incubation Time per Cycle Number of Cycles 
Initial Denaturation 98 ºC 30 s ×1 
Denaturation 94 ºC 15 s  
×35 Annealing 59 ºC 30 s 
Extension 68 ºC 120 s 
Final Extension 68 ºC 180 s ×1 
Hold 4 ºC Indefinite ×1 
 
LoxP2 
To amplify LoxP2, the procedure used to amplify LoxP1 was repeated with the following 
adjustments:  
1. LoxP2-F Primer was used in place of LoxP1-F Primer. 
2. LoxP2-R Primer was used in place of LoxP1-R Primer 
3. A LoxP2-positive DNA template was used to make the positive control instead of a 
LoxP1-homozygous DNA template. 
4. The following thermal cycling parameters were used: 
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Step Temperature Incubation Time per Cycle Number of Cycles 
Initial Denaturation 98 ºC 30 s ×1 
Denaturation 94 ºC 15 s  
×35 Annealing 58 ºC 30 s 
Extension 68 ºC 120 s 
Final Extension 68 ºC 180 s ×1 
Hold 4 ºC Indefinite ×1 
 
LoxP1/LoxP2 
To amplify LoxP1/LoxP2, the procedure used to amplify LoxP1 was repeated with the 
following adjustments: 
1. LoxP2-R Primer was used in place of LoxP1-R Primer 
2. A LoxP1/LoxP2,-positive DNA template was used to make the positive control instead 
of a LoxP1-homozygous DNA template. 
3. The following thermal cycling parameters were used: 
Step Temperature Incubation Time per Cycle Number of Cycles 
Initial Denaturation 98 ºC 30 s ×1 
Denaturation 94 ºC 15 s  
×35 Annealing 58 ºC 30 s 
Extension 68 ºC 180 s 
Final Extension 68 ºC 300 s ×1 
Hold 4 ºC Indefinite ×1 
 
LoxP/Neo 
To amplify a combination of LoxP and Neo, the procedure used to amplify LoxP1 was 
repeated with the following adjustments: 
1. Frt1-F Primer was used in place of LoxP1-F Primer. 
2. LoxP2-R Primer was used in place of LoxP1-R Primer. 
3. 0.25 µL 10 pmol/µL Neo-F Primer was added per sample to the Master Mix Solution. 
4. 9.00 µL Nuclease-Free H2O was added per sample to the Master Mix Solution instead 
of 9.25 µL Nuclease-Free H2O. 
5. A LoxP-homozygous/Neo-positive DNA template was used to make the positive 
control instead of a LoxP1-homozygous DNA template. 
6. The following thermal cycling parameters were used: 
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Step Temperature Incubation Time per Cycle Number of Cycles 
Initial Denaturation 98 ºC 30 s ×1 
Denaturation 94 ºC 15 s  
×35 Annealing 58 ºC 30 s 
Extension 68 ºC 180 s 
Final Extension 68 ºC 600 s ×1 
Hold 4 ºC Indefinite ×1 
 
FLPeR 
To amplify the FLPeR gene, the procedure used to amplify LoxP1 was repeated with the 
following adjustments:  
1. IMR 1348 Primer was used in place of LoxP1-F Primer. 
2. IMR 1349 Primer was used in place of LoxP1-R Primer. 
3. A FLPeR-positive DNA template was used to make the positive control instead of a 
LoxP1-homozygous DNA template. 
4. The following thermal cycling parameters were used: 
Step Temperature Incubation Time per Cycle Number of Cycles 
Initial Denaturation 98 ºC 30 s ×1 
Denaturation 94 ºC 15 s  
×35 Annealing 58 ºC 50 s 
Extension 68 ºC 90 s 
Final Extension 68 ºC 420 s ×1 
Hold 4 ºC Indefinite ×1 
 
Sox2-Cre 
To amplify the Sox2-Cre gene, the procedure used to amplify LoxP1 was repeated with 
the following adjustments:  
1. Cre-3 Primer was used in place of LoxP1-F Primer. 
2. Cre-1 Primer was used in place of LoxP1-R Primer 
3. A Sox2-Cre-positive DNA template was used to make the positive control instead of a 
LoxP1-homozygous DNA template. 
4. The following thermal cycling parameters were used: 
Step Temperature Incubation Time per Cycle Number of Cycles 
Initial Denaturation 98 ºC 30 s ×1 
Denaturation 94 ºC 15 s  
×35 Annealing 55 ºC 30 s 
Extension 68 ºC 45 s 
Final Extension 68 ºC 180 s ×1 
Hold 4 ºC Indefinite ×1 
20 
 
Agarose Gel Electrophoresis 
After thermal cycling was completed, 1.25 µL10x Gel Loading Buffer was added to each 
amplified DNA sample in order to facilitate the loading and tracking of the PCR samples. 
LoxP1, LoxP2, LoxP1/LoxP2, and Sox2-Cre PCR products were run on a 2.0% agarose 
gel, while LoxP/Neo and FLPeR PCR products were run on a 1.0% agarose gel. Each 
agarose gel was initially run at 100 V for 5 min, before running at 150 V until 
completion. Each gel was then imaged using a BIO-RAD ChemiDoc XRS Gel Scanner 
using the ultraviolet (UV) transillumination filter with the automatic exposure setting.  
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Materials 
Distal Tail Biopsy 
ARC Laboratories Kwik Stop
®
 Styptic Powder with Benzocaine 
National Band & Tag Company Stainless Steel Applicator 
Surgical Scissors 
DNA Extraction, Isolation, and Purification 
Fischer Scientific 1.5 mL Microcentrifuge Tubes 
Promega Nuclei Lysis Solution: Proprietary Ingredients 
0.5 M EDTA: 0.5 M EDTA in ddH2O 
Invitrogen Proteinase K (Fungal): 20 mg/mL Proteinase K (20 units/mg) in 50 mM Tris-HCl (pH 8.0), 3 
mM CaCl2, 50% glycerol 
Promega RNase A: 4 mg/mL RNase A in 10 mM Tris-HCl (pH 7.4), 1 mM EDTA (pH 8.0) 
Promega Protein Precipitation Solution: Proprietary Ingredients 
100% Isopropanol 
70% Ethanol 
Promega DNA Rehydration Solution: 10 mM Tris-HCl (pH 7.4), 1 mM EDTA (pH 8.0) 
Polymerase Chain Reaction (PCR) 
BIO-RAD C1000™ Thermal Cycler 
Fischer Scientific 1.5 mL Microcentrifuge Tubes 
Thermo Scientific PCR Tubes: 200 µL Thin-Walled Tubes with Flat Caps 
Sigma AccuTaq™ LA 10x Buffer: 500 mM Tris-HCl, 150 mM (NH4)2SO4 (pH 9.3), 25 mM MgCl2, 1% 
polysorbate 20 (TWEEN
®
 20) 
Thermo Scientific Fermentas dNTP Mix: 10 mM dATP, 10 mM dCTP, 10 mM dGTP, 10 mM dTTP in 
Nuclease-Free H2O 
Sigma Dimethyl Sulfoxide: 100% Dimethyl Sulfoxide (DMSO) 
Sigma AccuTaq™ LA DNA Polymerase: 5 units/µL DNA Polymerase in 20 mM Tris-HCl (pH 8.0), 100 
mM KCl, 0.1 mM EDTA, 1 mM dithiothreitol (DTT), 0.5% octylphenoxypolyethoxyethanol (IGEPAL
®
), 
50% glycerol 
Ambion DEPC-Treated Nuclease-Free Water: 0.2 µm Filtered, autoclaved 
Invitrogen Tris-EDTA (TE) Buffer 
Sigma Primers: 10 pmol/µLPrimer in TE Buffer 
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Primer Sequences 
Primer Sequence (5’ → 3’) 
LoxP1-F GCTTTGCTCTTAGCCTGCAC 
LoxP1-R CCAGATGCTCCTAGGCAAAA 
LoxP2-F TGCTATACGAAGTTATTAGGTGGA 
LoxP2-R CAGGACACATCTCTGCCAAG 
Frt1-F CACTCTTGCTTTCCAAGCTGT 
NEO-F ATAGCAGCTTTGCTCCTTCG 
IMR 1348 CACTGATATTGTAAGTAGTTTGC 
IMR 1349 CTAGTGCGAAGTAGTGATCAGG 
Cre-3 ATGCTTCTGTCCGTTTGCCG 
Cre-1 CCTGTTTTGCACGTTCACCG 
Agarose Gel Electrophoresis 
BIO-RAD ChemiDoc XRS Gel Scanner 
Invitrogen BlueJuice™ 10x Gel Loading Buffer: 10 mM Tris-HCl (pH 7.5), 10 mM EDTA, 0.3% 
Bromophenol Blue, 65% Sucrose 
Invitrogen UltraPure™ 10x TBE Buffer 
Invitrogen Ethidium Bromide (EtBr): 10 mg/mL EtBr 
2.0% Agarose Gel: 2.0% Agarose in 0.5x TBE Buffer, 0.50 mg/mL EtBr 
1.0% Agarose Gel: 1.0% Agarose in 0.5x TBE Buffer, 0.50 mg/mL EtBr 
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Results 
Sox2-Cre–Mediated Deletion of CXCL12 
A breeding scheme was constructed in order to confirm the location of the LoxP 
sequences inserted within the CXCL12 targeting allele. The previously generated 
CXCL12
loxPneo/+ 
non-chimeric mice were breed with Sox2-Cre hemizygous mice, 
resulting in the generation of CXCL12
+/-
;Sox2-Cre mice. These CXCL12
+/-
;Sox2-Cre 
progeny were then interbreed to generate neonatally lethal CXCL12
-/-
;Sox2-Cre mice and 
neonatally viable CXCL12
+/-
;Sox2-Cre and CXCL12
+/+
;Sox2-Cre mice. 
A. 
        
B. 
 
Figure 9. Sox2-Cre–Mediated Deletion of CXCL12. A. CXCL12 Targeting Allele. The LoxP1 site is 
directly downstream of the 8.1 kbp long 5’ arm, and the LoxP2 site is located directly upstream of the 4.0 
kbp short 3’ arm. The introduction of Cre recombinase with Sox2-Cre mice will facilitate the deletion of 
the 7.0 kbp LoxP-flanked region, resulting in the deletion of the CXCL12 gene coding region and the 
deactivation of the CXCL12 gene throughout the early embryo. B. CXCL12-Sox2-Cre Breeding Scheme. 
This breeding scheme diagrams the generation of CXCL12
-/-
;Sox2-Cre mice starting from CXCL12
loxPneo/+
 
mice. For the CXCL12 superscript, -/- denotes the deletion of the LoxP-flanked CXCL12 gene coding 
region in both alleles, +/- denotes the deletion of the LoxP-flanked CXCL12 gene coding region in one 
allele, and +/+ denotes the presence of the CXCL12 gene coding region in both alleles. 
CXCL12
loxPneo/+ 
× 
Sox2-Cre 
 
CXCL12
+/-
;Sox2-Cre 
× 
CXCL12
+/-
;Sox2-Cre
 
 
CXCL12
-/-
;Sox2-Cre 
 
CXCL12
+/-
;Sox2-Cre 
 
 
Neonatally Viable Neonatally Lethal 
CXCL12
+/+
 
Neonatally Viable 
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The interbreeding of CXCL12
LoxPneo/-
;Sox2-Cre mice resulted in 18 total progeny. Of the 
18 progeny, 5 (28%) were neonatally lethal and died within hours after birth, while 13 
(72%) were neonatally viable.  
 
              A            B 
 
 
 
 
 
 
            
               
            
 
 
 
        C                D 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10. Genetic Characterization of CXCL12
-/-
;Sox2-Cre Mice. CXCL12
-/-
;Sox2-Cre Mice were 
genetically characterized for A. LoxP1, B. LoxP2, C. LoxP1/LoxP2, and D. Sox2-Cre using PCR assays with 
gene specific primers.  
 
 
Table 2-A 
LoxP1 Genotype Banding Pattern 
Homozygous 261 bp 
Heterozygous 261 bp and 227 bp 
Wildtype 227 bp 
 
Table 2-C 
LoxP1LoxP2 Genotype Banding Pattern 
Homozygous 567 bp 
Heterozygous 567 bp 
Wildtype No Band 
 
Table 2. CXCL12-Sox2-Cre PCR Product Banding Patterns. A. LoxP1 Banding Pattern. B. LoxP2 
Banding Pattern. C. LoxP1/LoxP2 Banding Pattern. D.Sox2-Cre Banding Pattern. 
 
Table 2-B 
LoxP2 Genotype Banding Pattern 
Homozygous 335 bp 
Heterozygous 335 bp 
Wildtype No Band 
Table 2-D 
Sox2-Cre Genotype Banding Pattern 
Homozygous 260 bp 
Heterozygous 260 bp 
Wildtype No Band 
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As depicted in Figure 10, 3 of the 5 noenatally lethal CXCL12
-/-
;Sox2-Cre mice were 
genetically characterized with a combination of 4 PCR assays: LoxP1, LoxP2, 
LoxP1/LoxP2, and Sox2-Cre. As expected, all 3 CXCL12
-/-
;Sox2-Cre mice were LoxP1-
negative, LoxP2-positive, LoxP1/LoxP2-positive, and Sox2-Cre-positive, confirming that 
the LoxP-flanked region of the CXCL12 targeting allele was excised due to the 
introduction of Cre recombinase with Sox2-Cre mice. 
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FLPeR-Mediated Deletion of Neo
 
A breeding scheme was created with the purpose of generating CXCL12
loxP/loxP, FLPeR (-/-) 
mice (LoxP-homozygous, Neo-negative, FLPeR-negative), initially starting from the 
previously generated CXCL12
loxPneo/+ 
non-chimeric mice. These CXCL12
loxP/loxP, FLPeR (-/-) 
mice will then be used in future breeding schemes to generate CXCL12 conditional 
knockout mice. 
A. 
         
 
B. 
 
Figure 11. FLPeR-Mediated Deletion of Neo.
 
A. CXCL12 Targeting Allele. The Frt1 site is located 
directly upstream of the 1.8 kbp Neo coding region, and the Frt2 site is located directly downstream of the 
Neo coding region, both located within the 7.0 kbp LoxP-flanked region. The introduction of FLPeR will 
facilitate the deletion of the Frt-flanked region, resulting in the removal of the neomycin resistance gene.  
B. CXCL12-FLPeR
 
Breeding Scheme Diagram. This breeding scheme diagrams the generation of 
CXCL12
LoxP/LoxP, FLPeR (-/-)
 mice starting from CXCL12
LoxPneo/+
 mice. For the CXCL12-LoxPneo superscript, 
LoxPneo/LoxPneo denotes a homozygous genotype, LoxPneo/+ denotes a heterozygous genotype, and +/+ 
denotes a wildtype genotype. For the CXCL12-LoxP superscript, LoxP/loxP denotes a homozygous 
genotype, LoxP/+ denotes a heterozygous genotype, and +/+ denotes a wildtype genotype. For the FLPeR 
superscript, FLPeR (+/+) denotes a homozygous genotype, FLPeR (+/-) denotes a heterozygous genotype, 
and FLPeR (-/-) denotes a wildtype genotype.
 
CXCL12
LoxPneo/+ 
× 
FLPeR (+/+)
 
CXCL12
LoxP/+, FLPeR (+/-) 
× 
CXCL12
LoxP/+, FLPeR (+/-) 
 
CXCL12
LoxP/LoxP, FLPeR (-/-) 
× 
CXCL12
LoxP/LoxP, FLPeR (-/-) 
 
CXCL12
LoxP/LoxP, FLPeR (+/-) 
× 
CXCL12
LoxP/LoxP, FLPeR (-/-) 
 
CXCL12
LoxP/+, FLPeR (-/-) 
× 
CXCL12
LoxP/LoxP, FLPeR (-/-) 
 
CXCL12
LoxP/LoxP, FLPeR (-/-) 
 
CXCL12
LoxP/LoxP, FLPeR (-/-) 
 
CXCL12
LoxP/LoxP, FLPeR (-/-) 
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The previously generated CXCL12
LoxPneo/+ 
non-chimeric mice were breed with FLPeR-
homozygous mice to remove the Frt-flanked Neo gene, resulting in the generation of 
CXCL12
LoxP/+, FLPeR (+/-)
 mice. The CXCL12
LoxP/+, FLPeR (+/-)
 mice were then interbreed to 
generate CXCL12
LoxP/LoxP, FLPeR (-/-)
 mice with our target genotype. In order to generate a 
sufficiently large population of CXCL12
LoxP/LoxP, FLPeR (-/-) 
mice, various combinations of 
CXCL12
LoxP/LoxP
 and CXCL12
LoxP/+
 mice were breed together to improve the chances of 
generating progeny with the CXCL12
LoxP/LoxP, FLPeR (-/-) 
target genotype.  
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Generation of CXCL12
LoxP/LoxP, FLPeR (-/-) 
Mice 
CXCL12 Mice 3200-3210 
Two CXCL12
LoxP/+, FLPeR (+/-)
 mice were interbreed in order to generate CXCL12
LoxP/LoxP, 
FLPeR (-/-) 
mice. This breeding yielded 11 progeny (3200-3210), which were then 
genetically characterized with a combination of 4 PCR assays: LoxP1, LoxP2, LoxP/Neo, 
and FLPeR.  
 
        A            C 
                 
 
 
 
 
 
 
 
 
 
 
      
   B           D 
        
    
 
 
 
 
 
 
 
 
Figure 12. Genetic Characterization of CXCL12 Mice 3200-3210. CXCL12 mice 3200-3210 were 
genetically characterized for A. LoxP1, B. LoxP2, C. LoxP/Neo, and D. FLPeR using PCR assays with gene 
specific primers.  
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Table 3-A – LoxP1 
LoxP1 Genotype Band Size 
Homozygous 261 bp 
Heterozygous 261 bp and 227 bp 
Wild-Type 227 bp 
 
Table 3-C – LoxP/Neo 
LoxP Genotype Band Size Neo Genotype Band Size 
Homozygous 515 bp Homozygous 1.8 kbp 
Heterozygous 515 bp and 319 bp Heterozygous 1.8 kbp 
Wildtype 319 bp Wildtype No Band 
 
Table 3-D -FLPeR 
FLPeR Genotype Band Size 
Homozygous 725 bp 
Heterozygous 725 bp 
Wild-Type No Band 
 
Table 3. CXCL12-FLPeR PCR Product Banding Patterns. A. LoxP1 Banding Pattern. B. LoxP2 
Banding Pattern. C. LoxP/Neo Banding Pattern. D. FLPeR Banding Pattern. 
 
 
Sex/Tag # LoxP1 LoxP2 FLPeR Neo 
F3200 +/+ + - + 
M3201 +/- + + - 
M3202 -/- - + - 
M3203 +/- + - + 
M3204 +/- + + - 
F3205 -/- - + - 
F3206 +/- + + - 
F3207 +/+ + - - 
M3208 +/- + + - 
M3209 +/- + + - 
M3210 +/- + + - 
Table 4. Genetic Characterization of CXCL12 Mice 3200-3210. For LoxP1, +/+ denotes a homozygous 
genotype, +/- denotes a heterozygous genotype, and -/- denotes a wildtype genotype. For LoxP2, Neo, and 
FLPeR, + denotes a homozygous or heterozygous genotype and – denotes a wildtype genotype. 
 
This breeding yielded progeny with the following genotypes: 
CXCL12
LoxP/LoxP, FLPeR (-/-)
: F3207 
CXCL12
LoxP/+, FLPeR (+)
: M3201, M3204, F3206, M3208, 3209, 3210 
CXCL12
+/+, FLPeR (+)
: 3202, 3205  
CXCL12
LoxPneo/LoxPneo, FLPeR (-/-)
: F3200 
CXCL12
LoxPneo/+, FLPeR (+)
: 3203 
 
This breeding pair yielded 1 mouse (3207) with the CXCL12
LoxP/LoxP, FLPeR (-/-) 
target 
genotype, as well as 8 mice (3200, 3201, 3203, 3204, 3206, 3208, 3209, 3210) that can be 
used for breeding purposes in order to generate more mice with the target genotype. 
Table 3-B – LoxP2 
LoxP2 Genotype Band Size 
Homozygous 335 bp 
Heterozygous 335 bp 
Wild-Type No Band 
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Based on the results from the genetic characterization of CXCL12 mice 3200-3210, 3 
breeding pairs were initiated on April 10, 2012: 
1. F3207 (CXCL12
LoxP/LoxP, FLPeR (-/-)
) × M3201 (CXCL12
LoxP/+, FLPeR (+)
) 
2. F3200 (CXCL12
LoxPneo/LoxPneo, FLPeR (-/-)
) × M3208 (CXCL12
LoxP/+, FLPeR (+)
) 
3. F3206 (CXCL12
LoxP/+, FLPeR (+)
) × M3204 (CXCL12
LoxP/+, FLPeR (+)
) 
 
CXCL12 Mice 3243-3252 
Two CXCL12
LoxP/+, FLPeR (+/-)
 mice were interbreed, resulting in 10 progeny (3243-3252). 
The progeny were genetically characterized using a combination of 2 PCR assays: 
LoxP/Neo and FLPeR.   
                 A              B 
                           
 
 
 
 
 
 
 
 
 
 
 
Figure 13. Genetic Characterization of CXCL12 Mice 3243-3252. CXCL12 mice 3243-3252 were 
genetically characterized for A. LoxP/Neo and B. FLPeR using PCR assays with gene specific primers. 
 
Sex/Tag # LoxP1 LoxP2 FLPeR Neo 
F3243 +/- + + + 
F3244 -/- - + - 
F3245 -/- - + - 
F3246 +/- + + - 
M3247 -/- - + - 
M3248 -/- - + - 
M3249 +/- + + - 
M3250 +/- + + - 
M3251 -/- - + - 
M3252 +/- + + - 
Table 5. Genetic Characterization of CXCL12 Mice 3243-3252. For LoxP1, +/+ denotes a homozygous 
genotype, +/- denotes a heterozygous genotype, and -/- denotes a wildtype genotype. For LoxP2, FLPeR, 
and Neo, + denotes a homozygous or heterozygous genotype and – denotes a wildtype genotype. 
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This breeding yielded progeny with the following genotypes: 
CXCL12
LoxP/+, FLPeR (+)
: 3246, 3249, 3250, 3252 
CXCL12
LoxPneo/+, FLPeR (+)
: 3243 
CXCL12
+/+, FLPeR (+)
: 3244, 3245, 3247, 3248, 3251 
 
This breeding pair yielded no mice with the CXCL12
LoxP/LoxP, FLPeR (-/-)  
target genotype, 
but yielded 4 mice (3246, 3249, 3250, 3252) that can be used for breeding purposes in 
order to generate more mice with the target genotype. 
 
CXCL12 Mice 3268-3277 
Two CXCL12
LoxP/+, FLPeR (+/-)
 mice were interbreed, resulting in 10 progeny (3268-3277). 
The progeny were genetically characterized using a combination of 2 PCR assays: 
LoxP/Neo and FLPeR.  
 
               A             B 
 
 
 
 
 
 
 
 
 
 
Figure 14. Genetic Characterization of CXCL12 Mice 3268-3277. CXCL12 mice 3268-3277 were 
genetically characterized for A. LoxP/Neo and B. FLPeR using PCR assays with gene specific primers. 
Note: The bottom rung of the DNA ladder in the LoxP/Neo gel image ran off the bottom of the agarose gel. 
 
Sex/Tag # LoxP1 LoxP2 FLPeR Neo 
F3268 +/- + + - 
F3269 -/- - + - 
F3270 +/- + + - 
F3271 +/- + - - 
F3272 -/- - + - 
F3273 +/- + + + 
F3274 +/+ + - + 
M3275 -/- - + - 
M3276 +/- + + - 
M3277 -/- - + - 
Table 6. Genetic Characterization of CXCL12 Mice 3268-3277. For LoxP1, +/+ denotes a homozygous 
genotype, +/- denotes a heterozygous genotype, and -/- denotes a wildtype genotype. For LoxP2, FLPeR, 
and Neo, + denotes a homozygous or heterozygous genotype and – denotes a wildtype genotype. 
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This breeding yielded progeny with the following genotypes: 
CXCL12
LoxP/+, FLPeR (-/-)
: 3271 
CXCL12
LoxP/+, FLPeR (+)
: 3268, 3270, 3276 
CXCL12
+/+, FLPeR (+)
: 3269, 3272, 3275, 3277  
CXCL12
LoxPneo/LoxPneo, FLPeR (-/-)
: 3274 
CXCL12
LoxPneo/+, FLPeR (+)
: 3273 
 
This breeding pair yielded no mice with the CXCL12
LoxP/LoxP, FLPeR (-/-) 
target genotype, 
but yielded 5 mice (3268, 3270, 3271, 3274, 3276) that can be used for breeding purposes 
in order to generate more mice with the target genotype. 
 
CXCL12 Mice 3317-3325 
Two CXCL12
LoxP/+, FLPeR (+/-)
 mice were interbreed, resulting in 9 progeny (3317-3325). 
The progeny were genetically characterized using a combination of 2 PCR assays: 
LoxP/Neo and FLPeR.   
           A             B 
 
 
 
 
 
 
 
 
 
 
 
Figure 15. Genetic Characterization of CXCL12 Mice 3317-3325. CXCL12 mice 3317-3325 were 
genetically characterized for A. LoxP/Neo and B. FLPeR using PCR assays with gene specific primers. 
Note: The bottom 2 rungs of the DNA ladder in the LoxP/Neo gel image ran off the bottom of the gel. 
 
 
Sex/Tag # LoxP1 LoxP2 FLPeR Neo 
F3317 -/- - + - 
F3318 +/- + + - 
F3319 +/- + + - 
F3320 +/- + + - 
F3321 +/+ + - + 
M3322 +/- + + - 
M3323 +/- + + - 
M3324 +/- + + - 
M3325 +/+ + - + 
Table 7. Genetic Characterization of CXCL12 Mice 3317-3325. For LoxP1, +/+ denotes a homozygous 
genotype, +/- denotes a heterozygous genotype, and -/- denotes a wildtype genotype. For LoxP2, FLPeR, 
and Neo, + denotes a homozygous or heterozygous genotype and – denotes a wildtype genotype. 
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This breeding yielded progeny with the following genotypes: 
CXCL12
LoxP/+, FLPeR (+)
: 3318, 3319, 3320, 3322, 3323, 3324 
CXCL12
+/+, FLPeR (+)
: 3317  
CXCL12
LoxPneo/LoxPneo, FLPeR (-/-)
: 3321, 3325 
 
This breeding pair yielded no mice with the CXCL12
LoxP/LoxP, FLPeR (-/-) 
target genotype, 
but yielded 8 mice (3318, 3319, 3320, 3321, 3322, 3323, 3324, 3325) that can be used for 
breeding purposes in order to generate more mice with the target genotype. 
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Discussion 
Sox2-Cre–Mediated Deletion of CXCL12 
The breeding of Sox2-Cre mice with CXCL12
LoxPneo/+
 non-chimeric mice resulted in the 
generation of CXCL12
+/-
;Sox2-Cre progeny. The introduction of Cre recombinase 
resulted in the deletion of the LoxP-flanked CXCL12 gene coding region in one allele 
throughout the early embryo. The CXCL12
+/-
;Sox2-Cre mice were then interbreed, 
resulting in the generation of progeny with the following expected genotypic ratio: 
25% CXCL12
-/-
;Sox2-Cre 
50% CXCL12
+/-
;Sox2-Cre 
25% CXCL12
+/+
;Sox2-Cre 
 
In progeny with a CXCL12
-/-
;Sox2-Cre genotype, the introduction of Cre recombinase 
resulted in the deletion of the LoxP-flanked CXCL12 gene coding region in both alleles 
throughout the early embryo. The CXCL12 protein is essential for several processes 
during the embryonic stage of development, including the development of vasculature 
within the GI tract.
15
 Since the CXCL12 gene encodes for an essential protein during the 
embryonic stage of development, any progeny with a CXCL12
-/-
;Sox2-Cre genotype 
were expected to be neonatally lethal. Any progeny with a functional CXCL12 gene in at 
least one allele, including progeny with a CXCL12
+/-
;Sox2-Cre or CXCL12
+/+
;Sox2-Cre 
genotype, were expected to be neonatally viable.  
 
The interbreeding of CXCL12
+/-
;Sox2-Cre mice yielded a total of 18 progeny. Of the 18 
progeny, 5 (28%) were deceased within hours of birth, while 13 (72%) survived. The 
ratio of neonatally lethal and neonatally viable progeny closely approximated the 
expected ratio (25% lethal, 75% viable). Of the 5 neonatally lethal progeny, 3 were 
genetically characterized with PCR. As depicted in Figure 10, all 3 neonatally lethal mice 
were CXCL12
-/-
;Sox2-Cre (LoxP1-negative, LoxP2-positive, LoxP1/LoxP2-positive, and 
Sox2-Cre-positive); the genotype expected in mice that have undergone the Sox2-Cre-
mediated deletion of the CXCL12 gene.  
 
The neonatal lethality of CXCL12
-/-
;Sox2-Cre mice confirms that the CXCL12 targeting 
vector correctly inserted LoxP sequences both upstream of exon 1 and downstream of 
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exon 2 in the CXCL12 targeting allele. If the LoxP sequences were not flanking the 
CXCL12 gene coding region, then the introduction of Cre recombinase with Sox2-Cre 
mice would not have mediated the deletion of the CXCL12 gene and would therefore not 
have resulted in neonatal lethality in CXCL12
-/-
;Sox2-Cre mice. 
FLPeR-Mediated Deletion of Neo
 
The neomycin resistance gene was present within the CXCL12 targeting vector so that 
the successfully transfected ES cells could be selected for via neomycin treatment during 
the generation of CXCL12
LoxPneo/+
 chimeric mice. Since the Neo gene is located 
downstream of the second exon in the CXCL12 gene, within the LoxP-flanked gene 
coding region of the CXCL12 targeting allele, it has the potential to affect the 
transcription of the CXCL12 gene, the translation of the CXCL12 gene produce, and 
therefore the function of the CXCL12 protein. For this reason, the Neo gene was removed 
from the CXCL12 targeting allele via the introduction of the flippase reporter gene using 
FLPeR mice.  
 
A breeding scheme was constructed to generate CXCL12
LoxP/LoxP, FLPeR (-/-) 
mice without 
the Neo gene, starting from the previously generated CXCL12
LoxPneo/+
 non-chimeric mice. 
The CXCL12
LoxPneo/+
 mice were breed with FLPeR mice, resulting in a hypomorphic 
mutation in the F1 generation that removed the Frt-flanked Neo gene from the CXCL12 
targeting allele, resulting in the generation of The CXCL12
LoxP/+, FLPeR (+/-) 
mice. The 
CXCL12
LoxP/+, FLPeR (+/-) 
hypomorphic mice were then interbreed to generate 
CXCL12
LoxP/LoxP, FLPeR (-/-)
 mice; LoxP-homozygous, FLPeR-wildtype, hypomorphic mice 
with the Neo gene removed from both CXCL12 alleles. Several combinations of 
CXCL12
LoxP/LoxP, FLPeR (-/-)
, CXCL12
LoxP/+, FLPeR (-/-)
, and CXCL12
LoxP/LoxP, FLPeR (+/-)
 mice 
were interbreed to generate more mice with our target genotype.  
Generation of CXCL12
LoxP/LoxP, FLPeR (-/-) 
Mice 
As expected, the genetic characterization of CXCL12 –FLPeR mice 3200-3210 indicated 
that the LoxP1 banding pattern observed in Figure 12-A mirrors the LoxP/Neo banding 
pattern observed in Figure 12-C. This observation justifies the use of 2 PCR assays 
(LoxP/Neo and FLPeR) to fully characterize a set of CXCL12-FLPeR mice, instead of 4 
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PCR assays (LoxP1, LoxP2, FLPeR, and LoxP/Neo), allowing for a more time-efficient 
genetic characterization process. Two PCR assays were used to genetically characterize 
all subsequent CXCL12-FLPeR mice following the genetic characterization of CXCL12-
FLPeR mice 3200-3210. Also as expected, the LoxP1 banding pattern observed in Figure 
12-A is predictive of the LoxP2 banding pattern observed in Figure 12-B. LoxP1-
homozygous and LoxP1-heterozygous mice were all LoxP2-positive, while LoxP1-
wildtype mice were all LoxP2-negative. This observation indicates that the germline 
transmission of the CXCL12 targeting vector was successful, since LoxP1 and LoxP2 
were both detected in concert.  
 
After genetically characterizing CXCL12 mice 3200-3210 with PCR, 3 breeding pairs 
were initiated using mice from this group. The most important breeding pair was the 
breeding of F3207, the only mouse characterized with the CXCL12
loxP/loxP, FLPeR (-/-)
 target 
genotype, with M3201, a CXCL12
LoxP/+, FLPeR (+) 
mouse. Assuming that LoxP and FLPeR 
are passed on via a traditional Mendelian Inheritance pattern, there are two possible 
scenarios regarding the expected genotypic ratios of the progeny: 
 
Possibility 1: 
If M3201 is CXCL12
LoxP/+, FLPeR (+/-) the progeny’s genotypic ratio is expected to be: 
25% CXCL12
loxP/loxP, FLPeR (-/-)
 (Target Genotype) 
25% CXCL12
loxP/+, FLPeR (-/-)
  
25% CXCL12
loxP/loxP, FLPeR (+/-)
 
25% CXCL12
loxP/+, FLPeR (+/-) 
 
Possibility 2: 
If M3201 is CXCL12
LoxP/+, FLPeR (+/+), the progeny’s genotypic ratio is expected to be: 
50% CXCL12
loxP/loxP, FLPeR (+/-) 
50% CXCL12
loxP/+, FLPeR (+/-) 
 
If CXCL12 mouse 3201 is CXCL12
LoxP/+, FLPeR (+/-)
, 25% of the progeny are expected to 
have the CXCL12
loxP/loxP, FLPeR (-/-) 
target genotype. If the progeny includes both a male 
and a female mouse with the CXCL12
loxP/loxP, FLPeR (-/-) 
target genotype, they can be breed 
together to generate progeny that are all expected to have the target genotype. Any 
progeny with the CXCL12
loxP/loxP, FLPeR (-/-) 
target genotype can then be used in future 
breeding schemes. 
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Future Studies 
It is hypothesized that the ablation of CXCL12 from stromal fibroblasts will inhibit tumor 
angiogenesis and progression in breast cancer by modulating the tumor 
microenvironment. In future studies, this hypothesis will be tested by generating 
CXCL12 conditional knockout mice from the CXCL12
LoxP/LoxP, FLPeR (-/-)
 mice generated 
during this research project.  
A. 
        
 
B. 
 
Figure 16. FSP-Cre-Mediated Generation of CXCL12 Conditional Knockout Mice A. CXCL12 
Targeting Allele. The LoxP1 site is directly downstream of the 8.1 kbp long 5’ arm, and the LoxP2 site is 
located directly upstream of the 4.0 kbp short 3’ arm. The introduction of Cre recombinase with FSP-Cre 
mice will facilitate the deletion of the 7.0 kbp LoxP-flanked region, resulting in the deletion of the 
CXCL12 gene coding region and the deactivation of the CXCL12 gene from stromal fibroblasts in a 
cell/tissue type specific manner. B. CXCL12-FSP-Cre Breeding Scheme Diagram. This breeding scheme 
diagrams the generation of PyMT;CXCL12
sf-/sf-, FVB
 and PyMT;CXCL12
LoxP/LoxP, FVB
 mice starting from 
CXCL12
LoxP/LoxP, FLPeR (-/-)
 mice. The FVB superscript denotes an FVB background. For the CXCL12 
superscript, sf-/sf- denotes the deletion of the CXCL12 gene from stromal fibroblasts in both alleles, while 
LoxP/sf- denotes the deletion of CXCL12 gene from stromal fibroblasts in one allele.  
CXCL12
LoxP/LoxP, FLPeR (-/-) 
× 
FVB 
CXCL12
LoxP/LoxP, FVB 
× 
FSP-Cre
FVB 
 
CXCL12
LoxP/LoxP, FVB 
× 
MMTV-PyMT 
CXCL12sf-/sf-, FVB 
× 
MMTV-PyMT 
PyMT;CXCL12sf-/sf-, FVB 
PyMT;CXCL12
LoxP/LoxP, FVB
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In order to generate CXCL12 conditional knockout mice, CXCL12
loxP/loxP, FLPeR (-/-)
 mice 
will initially be breed with FVB wildtype mice, resulting in the generation of 
CXCL12
loxP/loxP, FVB 
mice. After five generations of CXCL12-FVB breeding, 
CXCL12
loxP/loxP, FVB
 male mice will be breed with FSP-Cre
FVB
 female mice to generate 
CXCL12
sf-/sf-, FVB
 progeny. The FSP-Cre-mediated deletion of the LoxP-flanked region 
from the CXCL12 targeting allele will result in the ablation of CXCL12 from stromal 
fibroblasts in a cell/tissue-type specific manner, resulting in the generation of CXCL12 
conditional knockout mice. Since CXCL12 will only be deleted in stromal fibroblasts, the 
CXCL12
sf-/sf-, FVB
 mice will still be neonatally viable. The neonatal viability of these 
CXCL12 conditional knockout mice allows them to sufficiently serve as models for the 
characterization of breast cancer growth and metastasis.
 
 
The CXCL12
sf-/sf-, FVB
 mice will then be breed with Murine Mammary Tumor Virus- 
Polyoma Middle T-Antigen (MMTV-PyMT) transgenic mice to generate PyMT; 
CXCL12
sf-/sf-, FVB
 mice, since the PyMT oncogene initiates the rapid onset and 
progression of mammary tumors. To determine the effects of the ablation of CXCL12 
from stromal fibroblasts on breast cancer metastasis, the tumor growth and progression of 
PyMT;CXCL12
sf-/sf-, FVB
 mice and PyMT;CXCL12
loxP/loxP, FVB
 control mice will be 
observed over a 2-6 month period. After 2, 3, 4, and 6 months, mammary glands from 
both the PyMT; CXCL12
sf-/sf-, FVB
 mice and the PyMT;CXCL12
loxP/loxP, FVB 
control mice 
will be analyzed for tumor growth by whole mount carmine, H&E Staining, proliferation 
(Ki67, cyclin D1), macrophage (F4/80), and angiogenesis (CD31). 
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